New drug targets Hard-to-Treat cancers with genetic flaw

NCT ID NCT06561685

Recruiting now Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 1 time

Summary

This study tests a new drug, LY4050784, in people with advanced solid tumors that have a specific change in the SMARCA4 gene. The goal is to see if the drug is safe and works, either alone or with other cancer treatments. About 340 adults whose cancer has not responded to standard treatments will take part. The study lasts up to 4 years.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adenocarcinoma lung neoplasm metastatic malignant neoplasm Neoplasm Metastasis non-small cell lung carcinoma SMARCA4-deficient sarcoma of thorax squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR METASTATIC SOLID TUMOR NON-SMALL CELL LUNG CANCER SMARCA4-DEFICIENT TUMOR

Contacts and locations

Locations

Aichi Cancer Center Hospital
RECRUITING

Nagoya, 464-8681, Japan
Charite-Universitatsmedizin Berlin
RECRUITING

Berlin, 10117, Germany
Columbia University Medical Center
RECRUITING

New York, New York, 10032, United States
Dana-Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States
Florida Cancer Specialists ORLANDO/DDU
ACTIVE_NOT_RECRUITING

Lake Mary, Florida, 32746, United States
Hospital Universitari Vall d'Hebron
NOT_YET_RECRUITING

Barcelona, 08035, Spain
Institut Bergonie
NOT_YET_RECRUITING

Bordeaux, 33 076, France
Institut Curie
RECRUITING

Paris, 75248, France
Institut Gustave Roussy-Gustave Roussy Cancer Center -DITEP
RECRUITING

Villejuif, 94800, France
Krankenhaus Nordwest
NOT_YET_RECRUITING

Frankfurt am Main, 60488, Germany
MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030-4009, United States
Massachusetts General Hospital
RECRUITING

Boston, Massachusetts, 02114, United States
Medical College of Wisconsin
RECRUITING

Milwaukee, Wisconsin, 53226, United States
Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States
National Cancer Center
RECRUITING

Ilsandong-gu, 10408, South Korea
National Cancer Center Hospital
RECRUITING

Chūōku, 104-0045, Japan
National Cancer Center Hospital East
RECRUITING

Kashiwa, 277-8577, Japan
Ohio State University Hospital
RECRUITING

Columbus, Ohio, 43210, United States
SCRI Oncology Partners
RECRUITING

Nashville, Tennessee, 37203, United States
Sarah Cannon Research Institute
RECRUITING

Nashville, Tennessee, 37203, United States
Sarah Cannon Research Institute at HealthOne
RECRUITING

Denver, Colorado, 80218, United States
Severance Hospital, Yonsei University Health System
RECRUITING

Seoul, 03722, South Korea
Shizuoka Cancer Center
RECRUITING

Nagaizumi-cho,Sunto-gun, 411-8777, Japan
South Texas Accelerated Research Therapeutics (START) Madrid - Hospital Fundacion Jimenez Diaz
RECRUITING

Madrid, 28040, Spain
The Cancer Institute Hospital of JFCR
RECRUITING

Kōtō City, 135-8550, Japan
The Catholic University of Korea, St. Vincent's Hospital
RECRUITING

Suwon, 16247, South Korea
UCLA
RECRUITING

Santa Monica, California, 90404, United States
USO-Virginia Cancer Specialists, PC
RECRUITING

Fairfax, Virginia, 22031, United States
Universitaetsklinikum Essen
NOT_YET_RECRUITING

Essen, 45147, Germany
University of Chicago
RECRUITING

New Lenox, Illinois, 60451, United States
University of Colorado Health Hospital
RECRUITING

Aurora, Colorado, 80045, United States
University of Miami
RECRUITING

Miami, Florida, 33136, United States
Vanderbilt-Ingram Cancer Center
RECRUITING

Nashville, Tennessee, 37232-6307, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.